FDA approves Juvmo for adults with Parkinson's disease

The approval introduces a selective dopamine D1/D5 receptor partial agonist as a new oral treatment option for adults with Parkinson's disease.

Juvmo (tavapadon) has been approved by the FDA for the treatment of Parkinson's disease in adults.

The approval follows the Phase III TEMPO clinical programme and brings a selective dopamine D1/D5 receptor partial agonist into the US Parkinson's treatment landscape.

Field	Content
Field	Content
Alert Type	FDA Approval
Product	Juvmo (tavapadon)
Indication	Parkinson's disease
Patient Population	Adults
Technology/Modality	Oral selective dopamine D1/D5 receptor partial agonist
Regulator	U.S. Food and Drug Administration
Regulatory Status	FDA approved
Clinical Programme	Phase III TEMPO programme
What Happened	FDA approved Juvmo for the treatment of Parkinson's disease in adults.
Why It Matters	The approval introduces a new oral treatment using selective partial agonism of dopamine D1 and D5 receptors.
Supporting Evidence	The regulatory programme was supported by the Phase III TEMPO studies.
Therapeutic Area	Neurology
Potential Impact	Juvmo adds another pharmacological option for the management of Parkinson's disease in adults.
Key Takeaway	Juvmo brings a selective D1/D5 receptor partial agonist to the US Parkinson's disease market.
What to Watch	Commercial launch, prescribing uptake and positioning within existing Parkinson's treatment pathways.
Primary Source	U.S. Food and Drug Administration
Relevant Date	25 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com